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radiation dose for patients and operators during complex endovascular
procedures
Giuseppe Panuccio, Roy K. Greenberg, Kevin Wunderle, Tara M. Mastracci,
Matthew G. Eagleton, William Davros
Background: A great deal of attention has been directed at the necessity
and potential for deleterious outcomes as a result of radiation exposure
during diagnostic evaluations and interventional procedures. We
embarked on this study in an attempt to accurately determine the amount
of radiation exposure given to patients undergoing complex endovascular
aortic repair. These measured doses were then correlated with radiation
dose estimates provided by the imaging equipment manufacturers that
are typically used for documentation and analysis of radiation-induced
risk.
Methods: Consecutive patients undergoing endovascular thoracoabdomi-
nal aneurysm (eTAAA) repair were prospectively studied with respect to
radiation dose. Indirect parameters as cumulative air kerma (CAK),
kerma area product (KAP), and fluoroscopy time (FT) were recorded
concurrently with direct measurements of dose (peak skin dose [PSD])
and radiation exposure patterns using radiochromatic film placed in the
back of the patient during the procedure. Simultaneously, operator
exposure was determined using high-sensitivity electronic dosimeters.
Correlation between the indirect and direct parameters was calculated.
The observed radiation exposure pattern was reproduced in phantoms
with over 200 dosimeters located in mock organs, and effective dose
has been calculated in an in vitro study. Scatter plots were used to eval-
uate the relationship between continuous variables and Pearson
coefficients.
Results: eTAAA repair was performed in 54 patients over 5 months, of
which 47 had the repair limited to the thoracoabdominal segment. Clin-
ical follow-up was complete in 98% of the patients. No patients had
evidence of radiation-induced skin injury. CAK exceeded 15 Gy in 3
patients (the Joint Commission on Accreditation of Healthcare Organiza-
tions [JCAHO] threshold for sentinel events); however, the direct
measurements were well below 15 Gy in all patients. PSD was measured
by quantifying the exposure of the radiochromatic film. PSD correlated
weakly with FT but better with CAK and KAP (r = 0.55, 0.80, and 0.76,
respectively). The following formula provides the best estimate of actual
PSD = 0.677 + 0.257 CAK. The average effective dose was 119.68 mSv (for
type II or III eTAAA) and 76.46 mSv (type IV eTAAA). The operator effective
dose averaged 0.17 mSv/case and correlated best with the KAP (r = 0.82,
P < .0001).
Conclusion: FT cannot be used to estimate PSD, and CAK and KAP represent
poor surrogate markers for JCAHO-defined sentinel events. Even when
directly measured PSDs were used, there was a poor correlation with clinical
event (no skin injuries with an average PSD >2 Gy). The effective radiation
dose of an eTAAA is equivalent to two preoperative computed tomography
scans. The maximal operator exposure is 50 mSv/year, thus, a single oper-
ator could perform up to 294 eTAAA procedures annually before reaching
the recommended maximum operator dose.* Full articles available online at www.jvascsurg.org
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doi:10.1016/S1078-5884(11)00115-8The contemporary management of splenic artery aneurysms
Ryan O. Lakin, James F. Bena, Timur P. Sarac, Samir Shah, Leonard P.
Krajewski, Sunita D. Srivastava, Daniel G. Clair, Vikram S. Kashyap
Objectives: The management of patients with splenic artery aneurysms
(SAAs) is variable since the natural history of these aneurysms is poorly delin-
eated. The objective of this study was to review our experience with open
repair, endovascular therapy, and observation of SAAs over a 14-year interval.
Methods: Between January 1, 1996 and December 31, 2009, 128 patients
with SAAs were evaluated. Sixty-two patients underwent surgical repair (n
= 13) or endovascular coil/glue ablation (n = 49), while 66 patients under-
went serial observation. The original medical records and computed tomog-
raphy (CT) imaging were reviewed. Statistical analyses were performed
using c2 or Fisher’s exact test for categorical patient characteristics and t-
test for continuous variables. Kaplan-Meier estimates for survival were
calculated. Mortality was verified via the Social Security Death Index.
Results: Patients (61  11 years, 69% female) were investigated for abdom-
inal symptoms (49%) or had the incidental finding of SAA (mean size, 2.4 
1.4 cm). Seven patients (5.5%) presented with rupture and were treated
emergently with two perioperative mortalities (29%). Patients requiring
surgical or endovascular treatment were more likely male (40% vs 21%, P =
.031), younger (58 vs 64 years; P = .004), and current smokers (18% vs 5%;
P = .035). Increased aneurysm calcification was associated with decreased
SAA size (P = .013). The mean aneurysm size at initial diagnosis was 1.67
cm for patients undergoing observation and 3.13 cm for the treated group
(P < .001). Endovascular repair was safe and durable with a mean 1.5-mm
regression in SAA size over 2 years. The mean rate of growth for observed
SAA was 0.2 mm/y. Ten-year survival was 89.4% (95% confidence interval:
82.0, 97.4) for all patients (observed group, 94.9%; treated group, 85.1%;
P = .18). No late aneurysm-related mortality was identified.
Conclusions: Ruptured SAAs are lethal. Large SAAs can undergo endovascu-
lar ablation safely with durable SAA regression. Smaller SAAs (<2 cm) grow
slowly and carry a negligible rupture risk.The minimally invasive management of visceral artery aneurysms and
pseudoaneurysms
Grant T. Fankhauser, William M. Stone, Sailendra G. Naidu, Gustavo S.
Oderich, Joseph J. Ricotta, Haraldur Bjarnason, Samuel R. Money, for the
Mayo Vascular Research Center Consortium
Objective: Minimally invasive methods (MIMs) are now available for the
management of visceral artery aneurysms and pseudoaneurysms (visceral
artery aneurysms [VAA]). The purpose of this study was to review our 10-
year experience with the MIM of treating VAA.
Methods: All patients evaluated from June 1999 to June 2009 with VAAs
were reviewed. Demographics, therapy, and results were analyzed.
Results: MIM was attempted in 185 aneurysms in 176 patients. Initial inter-
vention was successful in 98% ofaneurysms. Sixty-three (34%) aneurysms
were located in the splenic artery, 56 (30%) in the hepatic, 28 (15%) in the
574 Abstractsgastroduodenal, 16 (8.6%) in the pancreaticoduodenal, six (3.2%) in the
superior mesenteric, four (2.1%) in the gastric, four (2.1%) in the celiac,
four (2.1%) in the gastroepiploic, two (1%) in the inferior mesenteric, and
one (0.5%) in the middle colic artery. Pseudoaneurysms were more common
than true aneurysms (64% vs 36%). Bleeding was the indication for interven-
tion in 86 aneurysms (46%). Initial treatment was successful in 177 aneurysms
(98%). Reintervention was required in five (3%) aneurysms within 30 days.
Coiling was used alone in 139 aneurysms (75%) and in combination with at
least one other technique in 20 (11%) cases. Thirty-day aneurysm-related
mortality was 3.4% (six deaths). Five additional deaths occurred during 30-
day follow-up, although none was related to complications of the aneurysms
(2.8%).
Conclusions: MIM for visceral artery aneurysms can be used alone or in
combination to effectively treat VAAs in elective or emergent conditions.The distribution and size of ischemic lesions after carotid artery
angioplasty and stenting: Evidence for microembolization to terminal
arteries
Lei Zhu, Max Wintermark, David Saloner, Madison Flamel, Xian Mang Pan,
Joseph H. Rapp
Background: Much of the brain is perfused by penetrating arteries that are
the “single source” of blood to their surrounding tissues. These tissues
should be equally vulnerable to ischemia from embolic occlusion, but there
are questions about whether emboli have access to the penetrating arteries
serving the deep brain tissues. To examine this issue in humans we recorded
the number and distribution of new ischemic lesions on diffusion-weighted
magnetic resonance imaging (DWMRI) after carotid artery stenting (CAS),
a procedure producing showers of numerous small atheroemboli.
Methods: Twenty-nine men (aged 62-81) underwent 30 CAS procedures with
distal protection in place, and DWMRI 48 hours after the procedure docu-
mented new lesions had developed. Thirteen patients were asymptomatic,
and 16 had experienced recent symptoms ipsilateral to the treated carotid
stenosis. A DWMRI study was done in each patient 72 hours before the
procedure. All MRI studies were read by the same neuroradiologist.
Results: One patient sustained a minor stroke, which resolved. DWNRI found
131 new lesions (median, 3; range, 1-17; interquartile range, 2-4). Lesion
size was <5 mm in 96.6% and 5 to 10 mm in 3.1%. Lesions were ipsilateral
in 83.1% and contralateral in 16.9%. Lesions were in the distribution of the
middle cerebral artery (91.6%), posterior cerebral artery (6.1%), and supe-
rior cerebellar artery subclavian artery (2.0%). Most lesions were in the
cortex but at a depth where they were best described as cortical/subcortical
(90.8%). The rest were in the periventricular white matter (6.1%) and deep
gray matter (3.0%).
Conclusions: The ischemic areas developing after CAS were predominately
in the deeper layers of the cortex in the distribution of the middle cerebral
artery, but lesions were seen throughout the brain. The distribution of
lesions caused by CAS-induced embolization coincided with estimates of
blood flow to the respective areas of the brain. These data add to the
evidence implicating microemboli in ischemic pathologies throughout the
brain.Long-term outcomes for systematic primary stent placement in complex
iliac artery occlusive disease classified according to Trans-Atlantic Inter-
Society Consensus (TASC)-II
Shigeo Ichihashi, Wataru Higashiura, Hirofumi Itoh, Shoji Sakaguchi, Kiyoshi
Nishimine, Kimihiko Kichikawa
Purpose: To compare long-term outcomes of systematic primary stent
placement between Trans-Atlantic Inter-Society Consensus (TASC)-II C/D
disease and TASC-II A/B disease.
Methods: Between 1997 and 2009, endovascular treatments with primary
stent placement were performed for 533 lesions in 413 consecutive patients
with iliac artery occlusive disease. Median follow-up term was 72 months
(range, 1-144 months). Lesion severity in this retrospective study was classi-
fied according to TASC-II as type A in 134 patients (32%), type B in 154
patients (37%), type C in 64 patients (16%), and type D in 61 patients
(15%). Technical success rates, procedure time, complication rates, and
cumulative primary patency rates were compared between the complex
lesion group (TASC-II type C/D) and the simple lesion group (TASC-II type
A/B). Risk factors for in-stent restenosis were also analyzed.Results: Technical success rates in TASC-II C/D and A/B were both 99%.
Procedure times for TASC-II type A, B, C, and D lesions were 98  40, 124
 50, 152  55, and 183  68 minutes, respectively. Procedure time was
significantly longer in TASC-II C/D (167  63 minutes) than in TASC-II A/B
(112  47 minutes; P < .001). The complication rate was significantly higher
in TASC-II C/D (9%) than in TASC-II A/B (3%; P = .014). Cumulative primary
patency rates at 1, 3, 5, and 10 years were 90%, 88%, 83%, and 71% in
TASC-II C/D and 95%, 91%, 88%, and 83% in TASC-II A/B, respectively. No
significant differences were apparent between groups (P = .17; Kaplan-Meier
method, log-rank test). In multivariate analysis, lesion length was an inde-
pendent risk factor for in-stent restenosis (hazard ratio, 1.12, P = .03; 95%
confidence interval, 1.01-1.24).
Conclusions: Primary stent placement for complex iliac artery occlusive
disease provides acceptable long-term outcomes, although the procedure
takes relatively longer and is associated with a higher frequency of compli-
cations than for simple disease.Single-center experience in endovascular treatment of common femoral
artery obstructions
Frederic Baumann, Mirka Ruch, Torsten Willenberg, Florian Dick, Dai-Do Do,
Hak-Hong Keo, Iris Baumgartner, Nicolas Diehm
Objective: To evaluate the clinical efficacy of endovascular therapy of
symptomatic obstructions of the common femoral artery (CFA).
Methods: Consecutive series of patients undergoing endovascular therapy of
chronic CFA obstructions between 1995 and 2009 and who were followed
systematically within a prospectively maintained database. Clinical assess-
ment was based on current guidelines including ankle-brachial index (ABI)
and was performed at baseline and the day of discharge and then repeated
at 3, 6, and 12 months and annually thereafter. Technical success of inter-
vention was defined as a final residual diameter stenosis of <30%. Sustained
clinical improvement was defined as a sustained upward shift of at least one
category on the Rutherford classification compared with baseline without
the need for repeated target lesion revascularization (TLR) or amputation
in surviving patients. Limb salvage was defined as absence of a major (ie,
above the ankle) amputation. Survival analysis was performed using the
Kaplan-Meier method.
Results: Ninety-eight patients (38 women, mean age 72  11 years) pre-
sented with 104 ischemic limbs, 20 of which (19%) were classified as having
critical limb ischemia (CLI). Technical success rate was 98%. Stents were
placed in eight CLI patients (40%) and in 20 claudicants (24%). Mean ABI
improved from 0.28 to 0.54 (P < .001) in CLI patients and from 0.61 to
0.85 (P < .001) in claudicants. Mean follow-up was 16 months. Primary sus-
tained clinical improvement rates at 3, 6, 12, and 24 months were 55%, 55%,
40%, and 0% in CLI patients and 81%, 75%, 68%, and 52% in claudicants,
respectively. Limb salvage rates at 24 months were 94% in CLI patients and
100% in claudicants. After adjustment for confounding factors, presence of
ischemic ulcers (hazard ratio [HR], 4.7; 95% confidence interval [CI], 1.49-
14.85; P = .009), obstruction of the femoropopliteal arterial tract (HR,
3.9; 95% CI, 1.66-9.16; P = .002) and diabetes mellitus (HR, 2.3; 95% CI,
1.02-5.28; P = .045) were independently associated with lower rates of sus-
tained clinical improvement.
Conclusions: Endovascular therapy of CFA obstruction is associated with
high rates of sustained clinical success in claudicants with patent femoropo-
pliteal outflow. Presence of ischemic skin ulcers and diabetes mellitus,
however, are associated with impaired efficacy of endovascular CFA
treatment.Endovascular management of patients with critical limb ischemia: Long-
term results
Mark F. Conrad, Robert S. Crawford, Lauren A. Hackney, Vikram Paruchuri,
Christopher J. Abularrage, Virendra I. Patel, Glenn M. Lamuraglia, Richard P.
Cambria
Background: Although percutaneous intervention (PTA) is considered first-
line therapy for peripheral vascular disease in many scenarios, its role in
critical limb ischemia (CLI), wherein anatomic disease is more extensive,
remains unclear. In the present study, late (5-year) clinical and patency
data for PTA in CLI are defined.
Methods: From January 2002 to December 2007, 409 patients underwent
infrainguinal PTA  stent for CLI (Rutherford IV-VI) of 447 limbs. Primary
Abstracts 575patency, assisted patency, limb salvage, and survival were assessed using
Kaplan-Meier. Predictors of patency, limb salvage, and death were deter-
mined using multivariate models.
Results: Demographics included age (70  12 years old), diabetes (65.8%),
and dialysis dependence (13%). The superficial femoral artery was treated
in 58% of the patients, 16% were limited to the crural vessels, 38% had
multilevel treatment, and stents were placed in 26%. Eighty percent of
patients received postprocedure clopidogrel. Mean follow-up was 28
months (0-83). Five-year primary and assisted patency were 31%  0.04
and 75%  0.04, respectively. Limb salvage at 5 years was 74%  0.038.
Sixty-three patients had major amputations. Survival at 5 years was 39%
 0.03. Multivariate analysis identified dialysis dependence (P = .0005;
2.7 [1.6-4.8]), 1 vessel runoff (P = .02; 1.5 [1.1-2.0]), and warfarin use
(P = .001; 1.7 [1.25-2.3]) as negative predictors of primary patency, but
none of these were negative predictors of assisted patency. Dialysis
dependence (P = .006; 2.5 [1.3-4.8]), female gender (P = .02; 2.0 [1.1-
3.7]), and 1 vessel run-off (P = .04; 1.8 [1.0-3.2]) predicted limb loss.
Dialysis dependence (P = .0003; 2.3 [1.5-3.5]), diabetes (P = .04; 1.5
[0.5-2.1]), and poor run-off (P = .04; 1.6 [1.2-2.1]) were predictors of
mortality.
Conclusion: Although primary patency is low, excellent limb salvage rates
can be achieved in patients with CLI through close follow-up and secondary
interventions. These data, and the 12% annual death rate, validate PTA as
first-line therapy in patients with CLI.Ten-year experience with renal artery in-stent stenosis
Patrick A. Stone, John E. Campbell, Ali F. AbuRahma, Malik Hamdan, Mike
Broce, Aravinda Nanjundappa, Mark C. Bates
Background: Atherosclerotic renal artery stenosis (RAS) is the most common
cause of secondary hypertension. Renal stenting has become the treatment
of choice for RAS in most centers. Primary patency of RAS is well defined, butlimited data are available on outcomes of secondary interventions for treat-
ment of in-stent restenosis.
Methods: This was a retrospective analysis of a 10-year experience with
renal artery stenting in patients presenting with recurrent symptomatic
stenosis. End points included freedom from tertiary procedures, change in
baseline renal function by 20% measured by estimated glomerular filtration
rate (eGFR), patency confirmed by duplex imaging, long-term hypertension
response, freedom from hemodialysis, and survival.
Results: We reviewed 948 patients with 1150 treated renal arteries. Of
these, 107 patients (122 renal stents) returned with symptomatic in-stent
restenosis and required reintervention (target vessel revascularization
[TVR] rate, 10.6%): 97% had recurrent or worsening hypertension, and 67%
had worsening renal function. There were 69 women (64%) and 38 men
(35%) with an average age of 68.9 years. Mean follow-up was 35.5 months
(range, 1.0-104.7 months) for patency and 37.7 months (range, 0.03-100.9
months) for renal function (creatinine). Secondary interventions included
27 percutaneous transluminal angioplasties (PTAs), 10 PTAs with cutting
balloon, 77 repeat renal artery stenting, and 8 placements of drug-eluting
stents (DES). Twenty-five of the 122 arteries (20%) required tertiary inter-
ventions in 23 patients, a significantly higher TVR rate vs de novo interven-
tions (11%; P = .003). Freedom from tertiary interventions at 60 months was
similar among treatment groups undergoing PTA (66%), cutting balloon
(100%), stent (80%), and DES (75%; P = .348). Seventeen (16%) had an
increase of >20%, 50 (47%) had a decrease of >20%, and 30 (28%) had no
change in renal function. Ultimately 25 (23%) remained or progressed to
renal failure (eGFR < 30%), and 8 required hemodialysis. The survival rate
was 73% at 5 years. Mean follow-up for long-term hypertension response
was 3.2 years, with 56% improved, 28% with no improvement or deteriora-
tion, 16% without long-term data available, and no patients cured.
Conclusions: Secondary interventions for renal in-stent restenosis had
higher TVR vs de novo renal stents in this large series (21% vs 11%; P =
.003). Definitive recommendations on the best secondary treatment strategy
cannot be made because a medical treatment control group was not avail-
able for comparison.
